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Objective: Rapid plasma reagin (RPR) is frequently used to test women for maternal syphilis. Rapid syphilis
immunochromatographic strip tests detecting only Treponema pallidum antibodies (single RSTs) or both
treponemal and non-treponemal antibodies (dual RSTs) are now available. This study assessed the cost-
effectiveness of algorithms using these tests to screen pregnant women.Methods: Observed costs of maternal
syphilis screening and treatment using clinic-based RPR and single RSTs in 20 clinics across Peru, Tanzania,
and Zambia were used to model the cost-effectiveness of algorithms using combinations of RPR, single, and
dual RSTs, and no and mass treatment. Sensitivity analyses determined drivers of key results. Results: Although
this analysis found screening using RPR to be relatively cheap, most (N70%) true cases went untreated.
Algorithms using single RSTs were the most cost-effective in all observed settings, followed by dual RSTs,
which became the most cost-effective if dual RST costs were halved. Single test algorithms dominated most
sequential testing algorithms, although sequential algorithms reduced overtreatment. Mass treatment was
relatively cheap and effective in the absence of screening supplies, though treated many uninfected women.
Conclusion: This analysis highlights the advantages of introducing RSTs in three diverse settings. The results
should be applicable to other similar settings.
© 2015World Health Organization; licensee Elsevier. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Background
Antenatal syphilis causes a high burden of disease worldwide, with
over half of pregnancies in womenwith untreated syphilis leading to ad-
verse effects, including stillbirth, neonatal deaths, prematurity, and low
birth weight [1]. Despite syphilis treatment being effective and inexpen-
sive [2–4], many pregnant women remain undiagnosed owing to lack of
symptoms and the unavailability of laboratories equipped to offer syphi-
lis screening using traditional tests, such as rapid plasma reagin (RPR), in
most antenatal care (ANC) clinics [5–7]. Recent improvements in syphilis
screening have been made possible by the introduction of rapid syphilisand Tropical Medicine, 15–17
7 7721.
erris-Prestholt).
lsevier. This is an open access articletests (RSTs), which hold several advantages over the traditional RPR [8],
including not requiring laboratory infrastructure (e.g. electricity and
equipment) and their ability to be used correctly by different health pro-
fessionals [9]. As such, they can be performed at the point of care,
allowing for immediate treatment, andhave been shown to be acceptable
to patients [10,11]. However, most current RSTs are treponemal tests and
are therefore reactive to both current and past syphilis infections [9]. In
contrast, RPR is a non-treponemal test used to diagnose active infection
despite its low sensitivity [12,13]. New dual RSTs with both treponemal
and non-treponemal components have been recently developed [14,
15], but currently cost US $2.50 per test, which is two to ﬁve times
more than single treponemal tests.
Numerous studies have reported on the cost or cost-effectiveness of
antenatal syphilis screening interventions [2,16–20,35], while others
have modeled the cost-effectiveness of different screening approachesunder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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screening programs [3,26]. All of these studies show that antenatal
syphilis screening and treatment is highly cost-effective, but none has
compared a broad range of possible screening and treatment ap-
proaches, nor have they accessed a detailed dataset for multiple coun-
tries to parameterize their models.
Using cost and outcome data from evaluations of the RPR and single
RST in three countries, this study models the cost-effectiveness of ma-
ternal syphilis screening and treatment approaches in Peru, Tanzania,
and Zambia.
2. Materials and methods
The present analysis considers 10 screening and treatment ap-
proaches (Fig. 1). Four approaches involve single tests (Fig. 1A–D),
four entail a sequence of tests (Fig. 1E–H), and additional scenarios con-
sider no screening or treatment (Fig. 1NS) and mass treatment without
screening (Fig. 1I). Standardized facility-based data were used tomodel
the cost-effectiveness of each approach.
2.1. Setting and primary data
Between 2009 and 2010, study clinics in Peru, Tanzania, and Zambia
undertook operational research to estimate the cost-effectiveness of in-
troducing treponemal-based RSTs for the screening of maternal syphilis
in ANC and prevention of mother-to-child transmission of HIV pro-
grams [8,27]. Prior to introducing RSTs, a baseline assessment of current
syphilis screening using the RPR test was undertaken, including
collection of the numbers of women screened and treated, and the
associated costs (Supplementary Material S1). Data from these studies
[18,28; unpublished data] were used to parameterize the models.
Table 1 presents characteristics of the clinics in Peru, Tanzania, and
Zambia. These three settings represent a range of maternal syphilis
prevalence: 1.2% in Peru, 10.0% in Tanzania, and 12.4% in Zambia. Al-
though all three countries had a national policy of universal antenatal
syphilis screening, in the period prior to RST introduction, only about
60% of the studied facilities in these countries performed any syphilis
screening using RPR. Average country screening rates during the base-
line RPR period ranged from between 17.8% and 91.1%, improving to be-
tween 86.1% and 97.3% during the RST pilot. Average treatment rates
also improved from between 56.7% and 76.8% at baseline to betweenNS. No Screen A. RPR B. Single RST
E. Single RST RPR F. RPR Single RST G. Single RST Dual RST ++
RPR 
-+
Single RST
-+
Treat
Dual Trep/Non-Trep RST 
Trep +
Non-Trep +
Treat
All other 
results
Single RST
-+
RPR
-+
Treat
Single RST 
-+
Treat
No screening 
or
treatment
RPR 
-+
Treat with 2nd, 3rd dose)
Single RST
-+
Treat (1st dose)
Fig. 1. Screening and treatment approaches. +, Only non-treponemal antibody test results use
termine a positive case; Trep, Treponemal antibody test result; non-Trep, Non-treponemal ant77.4% and 93.9% during the RST pilot. These improvements can be at-
tributed to both the point-of-care nature of the RST test and the in-
creased supervision given to clinics [8]. More details on each setting
can be found elsewhere [18].
2.2. Modeling
Outcomes and costs were modeled initially at the average observed
scale of screening per country, converted to a common denominator of
1000 ANC attendees.
Data from each setting were collected on the number of women at-
tending the clinic, number screened, proportion reactive for theRPR and
single RST, number of women treated, and loss to follow-up (Table 1).
An active syphilis case is traditionally deﬁned asRPR positive, conﬁrmed
by a laboratory-based treponemal assay such as the Treponema pallidum
particle agglutination (TPPA) or Treponema pallidum hemagglutination
assay (TPHA). Field performance data (sensitivity and speciﬁcity) of
the single RST and clinic-based RPR test against a laboratory-based
RPR and TPPA test (Table 2) were used to estimate the proportion of re-
active tests that were likely true syphilis cases. For Peru, detailed data
were available to assess ﬁeld performance. For Zambia and Tanzania,
data from a ﬁeld performance evaluation in South Africa were used
[29]. The sensitivity of the dual RST was obtained from the literature
[14,30]. The percentage of women with a single positive or negative
RST result with different laboratory RPR and/or TPHA results is
presented in Supplementary Table S1.
The impact model estimated both the intermediate outcomes as
well as ﬁnal outcome measures: true cases treated, cases missed, and
overtreatment. Further details of how speciﬁc outputs for each algo-
rithm were calculated are given in Supplementary Material S2.
Standard approaches were used to estimate disability-adjusted life
years (DALYs) averted from treating pregnant women with syphilis
[17,19,26]. Adverse outcomes averted were obtained from Gomez
et al. [1]. Disability weights for congenital syphilis and low birth weight
were 0.315 and 0.291, respectively. Stillbirth was treated as a full life
lost and attributable adverse outcomes were captured through to end
of life; country-speciﬁc life expectancies and a 3%discount ratewere ap-
plied. Ranges applied in the sensitivity analysis were taken from the lit-
erature [3,31,32]. All DALY inputs are shown in Supplementary Table S2.
Total and unit costs were estimated. Total costs allowed for basic
comparisons of budget impact, while unit costs allowed for comparisonC. Dual RST ++ D. Dual RST +
H. Single RST Dual RST + I. Mass treatment
Single RST
-+
Dual Trep/Non-Trep RST 
Non-Trep +
Treat
All other 
results
Trep -
Non-Trep +
Treat
Dual Trep/Non-Trep RST 
Trep + 
Non-Trep +
Treat
All other 
results
Dual Trep/Non-Trep RST 
Non-Trep +
Treat
All other 
results
Treat all women 
presenting at 
ANC
d; ++, Dual RST – both treponemal and non-treponemal antibody test results used to de-
ibody test result; RPR, Rapid plasma reagin; RST, Rapid syphilis test.
Table 1
Overview of clinical screening by country.
Inputs RPR RST
Peru Tanzania Zambia Peru Tanzania Zambia
Overview
Number of clinics 6 9 5 6 9 5
True prevalence 1.25% 5.14% 9.04% 1.25% 5.14% 9.04%
Time period for RPR costing Mar–Nov 2009 Sep 2008–Jun 2009 Mar–Jul 2010 Feb–Nov 2010 Sep 2009–Jun 2010 Mar–Jul 2010
Program inputs
Percentage of ANC attendees screened 91.13% 17.79% a 79.91% 96.28% 86.14% 97.33%
(39.86–98.86) (0–83.40) (87.31–97.25) (68.09 – 100) (87.60–99.01)
Treatment rate 76.77% 74.07% 56.70% 88.57% 93.89% 77.36%
(33.33–100) (46.00–90.49) (0–95.00) (75.00–100) (83.81 – 100) (66.67–100)
Loss to follow-up 76.77% 74.07% 56.70% 88.57% 93.89% 77.36%
Number of attendees 1482.4 449.2 286.6 1482.4 1,190.1 989.8
(214–7002) (85.0–1464) (60.0–766) (214–7002) (196–1667) (162–2379)
Numbers testedb 1351 79.9 229 1427.3 1025.1 963.4
(119–6922) (0.0–217) (0.0–639) (205–6810) (196–3334) (142–2348)
Reactivity rates 0.39% 39.43% 4.69% 1.07% 9.89% 12.38%
(0.30–0.40) (9.09–58.82) (2.80–7.28) (0.68–2.33) (7.44–15.77) (7.14–23.58)
Numbers reactivec 5.2 31.5 10.8 15.2 101.3 119.3
(0.4–27.7) (10.0–95.0) (4.0–20.0) (1.4–67.1) (23.0–268) (21.0–180)
a In Tanzania, antenatal attendance was not collected within the cost study, therefor an average screening rate during the RPR period across all pilot clinics was used.
b Product of the Number of attendees and Percentage of ANC attendees screened.
c Product of the Reactivity rate and Numbers tested.
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tems approach (i.e. did not include patient costs). The model included
average clinic level costs for health systems inputs, ﬁxed clinic costs,
and variable costs at the patient level to estimate total clinic costs per
screening and treatment approach (Table 3). The model assumed that
acceptability/uptake of treatment for all approaches would be the
same as the single RST, including treating healthy mothers in the case
of mass treatment, with the exception of the RPR test, for which the ob-
served uptake was used. The model did not capture any averted treat-
ment costs attributable to treating infants born alive to an infected
mother or the costs of partner treatment. All costs are presented in
2012 US dollars.
Incremental cost-effectiveness ratios (ICERs; ratio of incremental costs
over incremental beneﬁts) are presented assuming a baseline of no
screening (approach NS), though ICERs were also estimated for transi-
tions from RPR to RST screening approaches. ICERs allow for comparisons
of the efﬁciency of resource allocations for competing interventions.
2.3. Sensitivity analysis
A sensitivity analysis was undertaken to assess how robust the con-
clusions were to variations in the model parameters. The present study
was unique in using data from different clinic settings in each country.
This allowed incorporation of the observed variation in different model
inputs as ranges in a probabilistic sensitivity analysis (PSA) considering
the cost-effectiveness of each algorithm in each country. Model parame-
ters not obtained from the clinics were obtained from the literature andTable 2
Test sensitivity and speciﬁcity characteristics and distributions assumed in probabilistic sensiti
Test characteristic Peru Tanzania and Zambia D
Sensitivity of single RSTa 77.2% (70.6%–83.0%) 70.5% (54.8%–83.2%) Bi
pr
si
Speciﬁcity of single RSTa 99.9% (99.9%–100%) 92.9% (90.7%–94.8%)
Sensitivity of clinic RPRa 55.7% (42.4%–68.5%) 45.7% (28.8%–63.4%)
Speciﬁcity of clinic RPRa 98.6% (97.1%–99.4%) 96.6% (95.1%–98.2%)
Sensitivity of dual RST against lab TPHA 96.4% (95.2%–97.6%) 96.4% (95.2%–97.6%) N
Speciﬁcity of dual RST against lab TPHA 99.1% (93.5%–97.0%) 99.1% (93.5%–97.0%)
Sensitivity of dual RST against lab RPR 88.6% (86.3%–90.7%) 88.6% (86.3%–90.7%)
Speciﬁcity of dual RST against lab RPR 98.6% (97.4%–99.3%) 98.6% (97.4%–99.3%)
Abbreviations: RPR, rapid plasma reagin; RST, rapid syphilis test; TPHA, Treponema pallidum he
a Compared against laboratory based RPR and TPHA test.uncertainty bounds were based on their 95% conﬁdence intervals (CIs).
All program and cost inputs were given a triangular distribution. Further
details on the ranges and distributions used for all parameters are given
in Tables 1–3, Supplementary Material S3, and Supplementary Table S2.
For the PSA, sets of parameters were randomly sampled 1000 times
from their uncertainty distributions for each algorithm and country. For
each sampled parameter set, the impact and cost-effectiveness of each
algorithm were estimated to determine the uncertainty in each model
output. The point estimates for each output were used to rank the algo-
rithms, whereas individual paired runs were used to assess the proba-
bility that one algorithm was more cost-effective than another in
terms of cost per DALY averted. The runs were also used to assess to
which model parameters the estimated cost and impact (DALYs
averted) of the best performing algorithm were most sensitive.
Univariate sensitivity analyses also explored how sensitive the cost-
effectiveness of algorithms A, B, and C (single RPR, RST, and dual test al-
gorithms) was to changes in the cost of the dual test, prevalence of
syphilis (0.5%, 1%, 5%, 10%), and increases in screening and treatment
rates up toWHO targets for elimination ofmother-to-child transmission
of syphilis (95% for both) [33].
3. Results
It is estimated that there would be 13, 51, and 90 true cases of
maternal syphilis per 1000 ANC attendees in Peru, Tanzania, and
Zambia, respectively (Table 4). In the absense of an ANC syphilis
screenng programme (approach NS) no cases woudl be treated,vity analysis.
istribution Source
nomial assumed on original sample size and
obability of success, then divided by sample
ze to get proportion
Peru data and Bronzan et al. 2007 [29]
ormal distribution Castro et al. 2010 [15]
magglutination assay.
Table 3
Clinic cost inputs and distributions (costs are presented in 2012 US dollars).a
Cost inputs RPR RST
Peru Tanzania Zambia Peru Tanzania Zambia
Fixed systems costs 494.15 760.04 1,840.54
(380–619) (684–893) (1502–2046)
Fixed clinic costs 1563.12 60.04 399.37 772.17 135.48 311.66
(24.64–7150) (45.61–76.89) (185–645) (320–2879) (93.06–253) (155–525)
RPR equipment 176.47 26.83 96.02
(10.61–724) (26.83–26.83) (23.14–136)
Screening costs
Personnel 1.66 0.36 1.74 0.21 0.17 0.45
(1.17–2.88) (0.24–0.47) (0.99–2.63) (0.05–0.36) (0.05–0.36) (0.05–0.36)
Test kits 0.11 0.07 0.02 0.94 1.29 0.72
Supplies and others 0.99 0.79 0.2 0.38 0.18 0.09
(0.78–1.28) (0.67–0.91) (0.11–0.3) (0.33–0.66) (0.04–0.42) (0.02–0.16)
Counselling costs Counseling and treatment costs
applied from RST observed costsNegative 0.19 0.03 0.15
(0.11–0.55) (0.02–0.08) (0.07–0.35)
Positive 1.13 0.14 0.33
(0.66–2.59) (0.05–0.25) (0.17–0.75)
Treatment costs
Personnel ﬁrst treatment 1.08 0.29 0.3
(0.783–1.94) (0.15–0.51) (0.23–0.36)
Supplies (incl. drugs) 0.63 0.74 0.69
(0.58–0.78) (0.61–0.95) (0.63–0.82)
Personnel second and third treatments 0.32 0.29 0.3
(0.23–0.77) (0.15–0.51) (0.23–0.36)
Abbreviations: RPR, rapid plasma reagin; RST, rapid syphilis test.
a Point estimates are averages across facilities in each country, and ranges are lowest and highest values observed across the clinics.
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assuming no treatment supply shortages (Fig. 2). Screening algorithms
that used the clinic-based RPR test performed worse than algorithms
using the RST, partly because of the poor sensitivity (43% to 55% when
compared with laboratory-based RPR and TPHA) of the RPR test, as
well as low screening rates for the RPR in these settings. Thiswas partic-
ularly the case in Tanzania, where RPR screening rates were just 18%.
Using the dual test on its own resulted in the greatest number of true
cases treated in all settings. Dual tests could trigger treatment based
solely on the non-treponemal result (algorithms D and H) or based on
both treponemal and non-treponemal reactivity (C and G). While the
former had slight beneﬁts in terms of fewermissed cases, it did increase
overtreatment by 16- to 20-fold when used alone (D comparedwith C),
or up to three timeswhen used to conﬁrm the single RST result (H com-
paredwith G). Finally, all sequenced algorithms reduced overtreatment
relative to single tests, although, generally, the number of missed cases
also increased owing to more false negatives.
3.1. Total costs
At the facility level (i.e. per 1000 ANC attendees screened), the RPR
test was the cheapest screening and treatment approach in Tanzania
(US $335) and Zambia (US $2180), while RST was the lowest cost
approach in Peru (US $2535). While RPR test kits cost very little
(US $0.02 to $0.11 per person screened), they are more labor intensive
and labor costs were higher in Peru.
3.2. Cost-effectiveness
The cost per DALY averted provided a comparison of the screening
and treatment algorithms relative to the baseline scenario of no screen-
ing. Approach B (single RST) was the most cost-effective diagnostic ap-
proach across all countries, while mass treatment was the most cost-
effective treatment approach in the higher prevalence settings
(Tanzania and Zambia). The dual test approaches (C, D, G, and
H) performed well in terms of identifying true cases while reducingovertreatment, but at US $2.50 per test, they were not as cost-effective
as approach B.
However, the single and dual RST algorithms cost much more than
just using the clinic-based RPR test (algorithm A) in Tanzania and
Zambia, highlighting that, in these settings, the RPR algorithm could
be the best option if the budget is constrained, although limited impact
is achieved (Supplementary Fig. S1). Conversely, in Zambia, mass treat-
ment (US $5.02 per DALY averted) could also be a cheaper option for
achieving greater impact albeit with considerable overtreatment. In
Peru, the single RST algorithm (B) was both the cheapest and the
most cost-effective option.
The incremental cost per facility of moving from using the clinic-
based RPR (algorithm A) to single RST (algorithm B) was US $2104
and US $1574 (US $0.95 and US $1.13 per woman screened) in
Tanzania and Zambia, respectively, while it would save US $1338 per fa-
cility (US $1.62 per woman screened) in Peru (Supplementary Fig. S1).
This would achieve an additional 133, 148, and 19 DALYs averted in
Tanzania, Zambia, and Peru, respectively, and was equivalent to an in-
cremental cost per DALY averted of US $15.79 and US $10.64 in
Tanzania and Zambia, respectively, while saving US $69 per DALY
averted in Peru.3.3. Probabilistic sensitivity analysis
The results of the PSA (Table 4 and Supplementary Fig. S2) empha-
sized the substantial variability/uncertainty in all model outputs. How-
ever, despite this uncertainty, the analysis suggested that theﬁrst choice
algorithm (B) using the single RST had the lowest cost per DALY averted
in over 74% ofmodel simulations in all three settings. Analyses of covari-
ance showed that the variability in the DALYs averted for this algorithm
was mainly due to variability in the single RST reactivity rate (account-
ing for 37% to 62% of variability) across different clinics and uncertainty
in the discount rate (27% to 53% of variability). Conversely, variability in
the total cost was mainly driven by variability in ANC attendance
(75% to 95%) across different clinics, followed by ﬁxed clinic costs
(1% to 17.7%) and screening coverage rates (0.2% to 8.2%). Despite
Table 4
Impact and cost-effectiveness of the 10 screening and treatment approaches (costs are presented in 2012 US dollars).a
NS. No
Screen
A. Clinic RPR B. Single RST C. Dual treat ++ D. Dual treat + E. Single RST→ RPR F. Clinic RPR→ Single RST G. Single RST→ Dual treat ++ H. Single RST→ Dual treat + I. Mass
treatment
Peru
True cases treated 0 4.9 8.2 9.2 9.5 8.2 3.8 7.1 7.3 11.1
(2.0–9.4) (5.8–16.5) (6.4–18.3) (6.7–18.9) (5.8–16.5) (1.6–7.3) (5.0–14.2) (5.2–14.7) (8.0–22.9)
Missed cases 12.5 7.6 4.3 3.3 3.1 4.3 8.7 5.4 5.2 1.4
(9.2–25.6) (6.1–18.9) (3.1–10.0) (2.5–8.2) (2.2–7.6) (3.1–10.0) (6.9–20.4) (4.1–12.3) (3.8–11.8) (0.4–4.2)
Over-treated 0 9.8 0.8 0.8 16.3 0.0 0.0 0.0 0.0 841.7
(2.0–15.6) (0.7–0.9) (0.1–0.4) (9.2–22.5) (0.0–0.0) (0.0–0.0) (0.0–0.0) 0.00.0 (705–900)
Total $ n.a. 3873.8 2535.5 4036.6 4103.7 3762.8 4761.9 2558.8 2559.6 3454.8
(2220–7549) (1973–4404) (3417–5874) (3485–5952) (2507–8918) (2777–9923) (2009–4424) (2010–4425) (2989–4810)
$/woman screened n.a. 4.25 2.63 4.19 4.26 3.91 4.95 2.66 2.66 n.a.
(2.40–8.1) (2.13–4.8) (3.7–6.3) (3.8–6.4) (2.7–9.5) (3.0–10.6) (2.2–4.8) (2.2–4.8)
$/woman treated n.a. 263.40 279.14 404.83 159.08 456.59 1,260.42 360.04 349.95 4.05
(160–820) (133–505) (205–679) (104–255) (191–1,061) (571–3,684) (166–659) (161–639) (4.0–5.6)
$/DALY averted n.a. 138.58 53.69 76.66 75.75 79.68 220.52 62.91 61.17 54.41
(56.9–544) (19.8–135) (27.6–182) (27.2–179) (27.9–252) (86.2–891) (24.0–158) (22.9–153) (21.2–130)
Tanzania
True cases treated 0 2.90 29.3 35.8 36.8 29.3 2.0 25.2 26.0 48.2
(0.4–23.0) (5.5–74.9) (6.4–94.6) (6.6–98.4) (5.5–74.9) (0.3–15.3) (4.8–64.4) (5.0–66.8) (8.9–130)
Missed cases 51.4 48.5 22.1 15.6 14.6 22.1 49.3 26.2 25.4 3.1
(9.3–142) (8.2–129) (3.8–74.1) (2.9–50.4) (2.6–47.4) (3.8–74.1) (8.5–13) (4.8–82.5) (4.6–81.1) (0.4–13.4)
Over-treated 0 3.9 50.7 1.7 20.3 1.2 0.3 0.6 1.8 760.5
(1.0–18.7) (31.6–67.0) (0.4–1.5) (12.5–26.9) (0.7–1.6) (0.1–1.3) (0.2–1.0) (1.0–2.5) (579–857)
Total $ 0 334.6 2438.3 3354.0 3412.7 2682.6 1152.6 2519.5 2525.1 2413.6
(202–1045) (2186–4253) (3000–5178) (3049–5239) (2417–4646) (975–3264) (2254–4339) (2260–4344) (1904–3118)
$/woman screened n.a. 1.9 2.8 3.9 4.0 3.1 6.5 2.9 2.9 n.a.
(1.4–3.5) (2.7–4.9) (3.7–6.0) (3.8–6.1) (2.9–5.5) (2.7–22.4) (2.7–5.1) (2.7–5.1)
$/woman treated n.a. 49.6 30.5 89.6 59.8 88.1 501.7 97.5 91.2 3.0
(23.1–103) (22.3–53.5) (38.9–432) (32.2–145) (39.8–389) (109–2,152) (44.3–468) (42.0–374) (2.6–3.7)
$/DALY averted n.a. 22.8 16.5 18.6 18.4 18.1 98.4 19.8 19.3 8.7
(5.7–155) (5.7–109) (6.0–124) (5.9–121) (6.4–116) (17.8–770) (7.0–130) (6.8–125) (2.2–56.2)
Zambia
True cases treated 0 17.6 48.0 58.7 60.3 48.0 12.4 41.3 42.5 70.0
(1.0–44.1) (13.5–126) (16.1–156) (16.4–161) (13.5–126) (0.7–29.9) (11.4–108) (11.8–112) (19.8–193)
Missed cases 90.4 72.9 42.5 31.8 30.1 42.5 78.1 49.1 47.9 20.5
(26.3–250) (22.7–218.8) (11.6–134) (9.5–98.7) (8.9–93.5) (11.6–133) (24.5–228) (14.2–150) (13.7–147) (4.6–66.3)
Over-treated 0 12.7 45.2 1.5 18.1 1.1 0.8 0.6 1.6 683.0
(1.2–19.7) (28.1–59.2) (0.3–1.3) (11.2–22.9) (0.6–1.4) (0.1–1.4) (0.2–0.8) (0.9–2.1) (499–768)
Total $ 0 2,180.3 3,754.7 5,400.8 5,447.4 4,606.8 4,476.4 3,990.5 3,996.1 2,012.8
(708–2843) (2558–7039) (4139–8729) (4188–8771) (3132–8931) (2186–8304) (2768–7426) (2774–7432) (1581–2522)
$/woman screened n.a. 2.2 3.9 5.6 5.6 4.7 4.6 4.1 4.1 n.a.
(0.7–3.0) (2.7–7.3) (4.4–9.1) (4.4–9.1) (3.3–9.6) (2.3–8.8) (2.9–7.6) (2.9–7.7)
$/woman treated n.a. 72.1 40.3 89.8 69.5 94.0 338.8 95.3 90.7 2.7
(33.0–427) (20.0–81.5) (32.4–329) (29.2–177) (34.7–308) (121–4,535) (35.1–327) (34.0–300) (2.5–3.2)
$/DALY averted n.a. 25.5 16.1 18.9 18.6 19.8 63.1 19.9 19.3 5.0
(8.0–254) (4.3–76.5) (5.0–86.9) (4.9–84.2) (5.7–92.6) (19.6–1014) (5.6–91.9) (5.5–88) (1.3–21.8)
Abbreviations: + Algorithms using only non-treponemal test result; ++ Algorithms using treponemal and non-treponemal test results of the dual test; Arrow indicates second test following a positive ﬁrst test; n.a., Not available; DALY, disability-
adjusted life year; RPR, rapid plasma reagin; RST, rapid syphilis test.
a Ranges for each outcome are 2.5 to 97.5 percentile range from probabilistic sensitivity analysis.
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Fig. 2. Comparison of approach by key indicators: health impact (total true cases averted), budget impact (total cost), and cost-effectiveness (cost per DALY averted), by country and
screening and treatment approach. Costs are presented in 2012 US dollars. 0. None (No screening); A. Clinic RPR; B. Single RST; C. Dual treat ++; D. Dual treat +; E. Single
RST→ RPR; F. Clinic RPR→ Single RST; G. Single RST→ Dual treat ++; H. Single RST→ Dual treat +; I. Mass treatment.
Fig. 3. The relationship between cost-effectiveness (US $/DALY averted) and true syphilis
prevalence. Costs are presented in 2012 US dollars.
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in the costs and impact, the uncertainty analysis suggests the results
were largely robust and insensitive to this variability.
3.4. Univariate sensitivity analysis
Univariate sensitivity analysis showed that, for the dual RST (C) to
achieve the same cost per DALY averted as the single RST (B), the dual
test price would need to drop from US $2.50 to US $2.07 in Tanzania,
US $1.67 in Zambia, and US $1.24 in Peru. There was also a strong in-
verse relationship between the cost per DALY averted and true syphilis
prevalence because greater impact was achieved at higher prevalence
and the ﬁxed costs of screening were spread between these outcomes
(Fig. 3). However, this did not affect the relative ordering of the algo-
rithms, except for mass treatment, which became relatively cheaper in
higher prevalence settings.
The cost-effectiveness of screening and treatment could be im-
proved if the rates were strengthened. With the RPR, average ANC
screening rates were 18% to 91% with treatment rates of 57% to 77%. In-
troduction of the RST improved this, with screening rates increasing to
86% to 97% and treatment rates to 77% to 94%. If countries achieve the
WHO target of 95% for screening and treatment [33], the cost per
DALY averted would drop marginally (3%) for RST to US $50, US $16,
and US $14 in Peru, Tanzania, and Zambia, respectively. Greaterimprovements (42%)would occur for the RPR because of the lower test-
ing and treatment rates, and this would become the most cost-effective
approach in Tanzania.
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The present study used observed data from clinic-based evaluations
of RPR and RST in Peru, Tanzania, and Zambia to model the cost-
effectiveness of 10 screening and treatment approaches being explored
byWHO and other partners. Despite being the most widely applied ap-
proach, maternal syphilis screening using the RPR test leaves many
women unscreened, results in high numbers of missed cases, and con-
siderable overtreatment.
This study shows how the introduction of a treponemal-based RST
increased the access to and effectiveness of screening, identifying
most (54% to 66%) true cases at the initial visit, encouraging high treat-
ment rates, and was more cost-effective than any other screening ap-
proach considered in all settings. However, some policymakers are
concerned about overtreatment owing to the failure of treponemal
tests to distinguish between past and current syphilis. Sequentially
combining tests or using new dual treponemal and non-treponemal
RSTs could greatly improve this issue. However, this would require a
budget expansion of at least 38% above what is needed for the single
RST at current prices. Nevertheless, if prices halve, the dual RST would
be the most cost-effective.
To our knowledge, this is the ﬁrst study to estimate the cost-
effectiveness of mass treatment for averting adverse birth outcomes at-
tributable tomaternal syphilis infection, showing that, in high prevalence
settings, mass treatment can be the cheapest alternative with the fewest
missed cases. An advantage of mass treatment is that it overcomes the
problem of stockouts of syphilis testing supplies, which can occur with
both RPR and RST. Mass treatment could also reduce the stigma related
to a positive syphilis test if all pregnant women are treated regardless
of status. However, mass treatment is a controversial approach. A core
concern is adverse reaction to benzathine penicillin, which occurs in ap-
proximately 2 per 1 000 000 people treated [34]. Further concerns arise
around the inability to identify infected partners, the feasibility of deliver-
ing treatment to all ANC attendees in terms of infrastructure and human
resource capacity on the providers’ side, and the willingness of pregnant
women to accept treatment without knowingly being infected. It would
be useful for future syphilis screening and treatment guidelines to evalu-
ate the advantages and disadvantages of mass treatment, particularly
during diagnostic and supply stockouts. Ultimately, it is a decision that
must be taken by country policymakers and practitioners considering
the epidemiologic context and balancing the potential risks and beneﬁts
to mothers and their infants.
As with all cost-effectiveness analyses, this analysis has its strengths
and limitations. While site-speciﬁc sensitivity and speciﬁcity data were
available for the single RST and clinic-based RPR for Peru, clinical perfor-
mance data for Tanzania and Zambia had to be obtained from South
Africa [29]. It was assumed that no treatment was available for infants
born to mothers infected with syphilis, which may have overestimated
the beneﬁt and costs of the interventions. Further, averted treatment
costs among live-born infants affected by maternal syphilis and treat-
ment beneﬁts among adults were not accounted for. This renders the
cost-effectiveness results conservative relative to the no treatment sce-
nario. While there was a large variation between clinics, the sample of
clinics was too small to explore key clinic level drivers of variation in
cost-effectiveness such as geographical remoteness and scale. In the
current approach, averages per clinic were considered, treating each
clinic as an observation so as to capture variation across clinics. Ideally,
this would have been weighted appropriately relative to the number
and type of facilities in each country.
5. Conclusions
The present study models the cost-effectiveness of different screen-
ing and treatment approaches for maternal syphilis using detailed cost-
ing and clinical data. This strengthens the realism and generalizability of
the results compared with studies drawing on inputs from publishedsources. The analysis suggested that the single RST should be considered
the best screening option unless the price of the dual RST is signiﬁcantly
reduced. Because of its poor performance, the clinic-based RPR should
only be considered in severely resource-restricted settings where it
may be the cheapest option, butmissesmany cases. In contrast, sequen-
tial testing regimens were costly but could minimize overtreatment.
More research is required to determine the optimal situations for
mass treatment, no treat the highest number of cases at low cost but
without resulting in substantial overtreatment, which would lead to
ethical concerns.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.ijgo.2015.04.007.
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